Cosmo Pharmaceuticals N.V. (FRA: C43)

Market Cap	1.03B
Revenue (ttm)	185.36M
Net Income (ttm)	69.57M
Shares Out	n/a
EPS (ttm)	4.32
PE Ratio	14.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jul 10, 2024

Volume	47
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	53.00 - 86.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 14, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 325
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C43